Treatment of diseases through conventional small molecular drugs and drug delivery systems was revolutionized by the advent of biologics. Today, biomedicine sits on the cusp of a new revolution: the use of microbial and human cells as versatile therapeutic engines.
The advent of cellular medicine will require the development of foundational cellular engeneering science.The current scientific, regulatory and economic issues mandate a systematic guidelines about the promising “third pillar” of therapeutics.Safety concerns and predictability about cell based treatments are policy driven at Prasad research foundation and Prasad hospitals.
Prasad Research Foundation (PRF) is a unique platform for Researchers and Clinicians to identify the potential niche in the use of human and microbial cells as therapeutic entities. In principle, cells have therapeutic capabilities that are distinct from those of small molecules and biologics .
Cells can sense diverse signals, behaving as part drug and part device they move to specific sites in the body all in the context of specific tissue environment. move to specific sites in the body, integrate inputs to make decisions, and execute complex response behaviours—all in the context of a specific tissue environment.
These attributes could potentially be harnessed to treat infections, autoimmunity, cancers, metabolic diseases, and tissue degeneration as well as realizing tissue repair and regeneration. Indeed, pioneering clinical trials have highlighted the benefits of using cells as therapeutic agents.
Prasad research foundation and Prasad hospitals ensure a safe therapeutic setting and comply with scientific, regulatory and economic issues for cell based therapeutics
Our clinicians and researchers with a deep mechanistic understanding of cell biology are poised to harness novel technologies in cell based therapies and cell free products against a broad range of diseases.
Prasad research foundation strictly adheres to the Indian Council of Medical Research (ICMR) guidelines of 2017 in the usage of Hematopoietic progenitor stem cells (HPSC) derived from discarded placenta and umbilical cord in clinical research as well as therapy for patients with extreme medical conditions.